Aspire Biopharma Holdings (ASBP) Selling, General & Administrative (2021 - 2026)
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Selling, General & Administrative (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 1.75 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 1.92 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 582.20 Mn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 662.10 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 216.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | -417.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 709.70 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 165.53 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | 970,211.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 970,211.00 |
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 512,993.00 |
| Jun 30, 2025 | 395,692.00 |
| Mar 31, 2025 | 15.07 Mn |
| Dec 31, 2024 | 529,616.00 |
| Sep 30, 2024 | 191,578.00 |
| Jun 30, 2024 | 86,423.00 |
| Mar 31, 2024 | 132,804.00 |
| Dec 31, 2023 | 402,615.00 |
| Sep 30, 2023 | 324,742.00 |
| Jun 30, 2023 | 288,246.00 |
| Mar 31, 2023 | 324,565.00 |
| Dec 31, 2022 | 314,030.00 |
| Sep 30, 2022 | 255,257.00 |
| Jun 30, 2022 | 297,840.00 |
| Mar 31, 2022 | 109,219.00 |
| Dec 31, 2021 | 755.00 |
| Sep 30, 2021 | 15,310.00 |